{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T10:52:59Z","timestamp":1761216779270},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Should adjuvant chemotherapy for resected non-small cell lung cancer (NSCLC) be the standard of care? That question has been much debated since the presentation of results from the International Adjuvant Lung Cancer Trial (IALT) in May 2003 at the plenary session of the American Society of Clinical Oncology annual meeting. The IALT study showed a statistically significant survival advantage for patients treated with cisplatin-based adjuvant chemotherapy. The topic of adjuvant chemotherapy permeated the Tenth World Conference on Lung Cancer held from August 10\u201314, 2003 in Vancouver, Canada. Updated results of the IALT study were presented along with results from the Big Lung Trial from the United Kingdom and the Adjuvant Lung Project Italy trial, neither of which showed a significant survival benefit for adjuvant chemotherapy. How to put the IALT data into practice remains controversial, and leading lung cancer experts have not reached a consensus.<\/jats:p>\n               <jats:p>Platinum-based doublets that include a taxane, vinorelbine, or gemcitabine remain the standard of care for the first-line treatment of metastatic NSCLC. However, there may soon be a new option for second-line treatment. A randomized study of pemetrexed in the second-line setting found efficacy similar to that of docetaxel given every 3 weeks, with less toxicity.<\/jats:p>\n               <jats:p>Gefitinib was recently approved by the U.S. Food and Drug Administration for the treatment of advanced NSCLC following platinum-based chemotherapy and docetaxel. However, concerns have arisen about toxicity due to reports of interstitial pneumonitis from Japan. The observed incidence of interstitial pneumonitis from the data available to date is approximately 1%. Which patients derive the most benefit from gefitinib? It appears that lifetime nonsmokers and patients with bronchioloalveolar histology have the highest probability of disease response.<\/jats:p>","DOI":"10.1634\/theoncologist.9-2-232","type":"journal-article","created":{"date-parts":[[2004,8,24]],"date-time":"2004-08-24T21:38:39Z","timestamp":1093383519000},"page":"232-238","source":"Crossref","is-referenced-by-count":12,"title":["Highlights from the Tenth World Conference on Lung Cancer"],"prefix":"10.1093","volume":"9","author":[{"given":"Tracey L.","family":"Evans","sequence":"first","affiliation":[{"name":"The University of Pennsylvania Medical Center\u2014Presbyterian, Division of Hematology\/Oncology, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2004,4,1]]},"reference":[{"key":"2021122209333294200_R1","article-title":"Results of the randomized International Adjuvant Lung Cancer Trial (IALT): cisplatin-based chemotherapy (CT) vs no CT in 1867 patients (PTS) with resected non-small cell lung cancer (NSCLC) [abstract]","volume-title":"Tenth World Conference on Lung Cancer","author":"LeChevalier","year":"2003"},{"key":"2021122209333294200_R2","first-page":"291a","article-title":"The Big Lung Trial: determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting","volume":"21","author":"Stephens","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209333294200_R3","article-title":"The Big Lung Trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC)","volume-title":"Preliminary results in the surgical setting [abstract]. Tenth World Conference on Lung Cancer","author":"Waller","year":"2003"},{"key":"2021122209333294200_R4","volume-title":"Adjuvant Lung Project Italy (ALPI): the Italian\/EORTC-LCCG randomised trial of adjuvant cisplatin-based chemotherapy in completely resected non-small cell lung cancer (NSCLC) [abstract]. Tenth World Conference on Lung Cancer","author":"Scagliotti G on behalf of the ALPI\/EORTC-LCCG investigators","year":"2003"},{"key":"2021122209333294200_R5","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/jnci\/djg059","article-title":"Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer","volume":"95","author":"Scagliotti","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2021122209333294200_R6","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1378\/chest.111.6.1710","article-title":"Revisions in the International System for Staging Lung Cancer","volume":"111","author":"Mountain","year":"1997","journal-title":"Chest"},{"key":"2021122209333294200_R7","first-page":"257","article-title":"PORT Meta-analysis Trialists Group","volume":"352","author":"Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials","year":"1998","journal-title":"Lancet"},{"key":"2021122209333294200_R8","first-page":"899","article-title":"Non-small Cell Lung Cancer Collaborative Group","volume":"311","author":"Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials","year":"1995","journal-title":"BMJ"},{"key":"2021122209333294200_R9","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/annonc\/mdf332","article-title":"Phase III randomised trial comparing paclitaxel\/carboplatin with paclitaxel\/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial","volume":"13","author":"Rosell","year":"2002","journal-title":"Ann Oncol"},{"key":"2021122209333294200_R10","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2003.12.046","article-title":"Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group","volume":"21","author":"Fossella","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122209333294200_R11","doi-asserted-by":"crossref","DOI":"10.1016\/S0169-5002(03)91660-6","article-title":"Two second-line docetaxel dose-schedules in advanced non-small cell lung cancer (NSCLC): a Spanish Lung Cancer Group (SLCG) phase III trial [abstract]","volume-title":"Tenth World Conference on Lung Cancer","author":"Camps","year":"2003"},{"key":"2021122209333294200_R12","doi-asserted-by":"crossref","DOI":"10.1016\/S0169-5002(03)91658-8","article-title":"A phase III study of pemetrexed vs. docetaxel in patients with advanced non-small cell lung cancer (NSCLC) who were previously treated with chemotherapy [abstract]","volume-title":"Tenth World Conference on Lung Cancer","author":"Shepherd","year":"2003"},{"key":"2021122209333294200_R13","doi-asserted-by":"crossref","DOI":"10.1016\/S0169-5002(03)91659-X","article-title":"A phase III trial comparing weekly and three weekly docetaxel in second line treatment of patients with advanced non-small cell lung cancer (NSCLC) [abstract]","volume-title":"Tenth World Conference on Lung Cancer","author":"Schuette","year":"2003"},{"key":"2021122209333294200_R14","first-page":"625a","article-title":"Effect of quality-of-life (QoL) of weekly vs 3-weekly docetaxel (D) in second-line treatment of advanced non-small cell lung cancer. The DISTAL randomized phase 3 study","volume":"22","author":"Gridelli","year":"2003","journal-title":"Proc Amer Soc Clin Oncol"},{"key":"2021122209333294200_R15","first-page":"2a","article-title":"Phase III single-blinded study of pemetrexed + cisplatin vs. cisplatin alone in chemonaive patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2002","journal-title":"Proc Amer Soc Clin Oncol"},{"key":"2021122209333294200_R16","article-title":"Clinical experience with gefitinib (\u2018Iressa\u2019, ZD1839): an overview of safety and tolerability [abstract]","volume-title":"Tenth World Conference on Lung Cancer","author":"Forsythe","year":"2003"},{"key":"2021122209333294200_R17","article-title":"Clinical, pathologic, and molecular characteristics of NSCLC patients sensitive to gefitinib [abstract]","volume-title":"Tenth World Conference on Lung Cancer","author":"Miller","year":"2003"},{"key":"2021122209333294200_R18","first-page":"292a","article-title":"A phase II trial of ZD1839 (\u2018Iressa\u2019) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens","volume":"21","author":"Kris","year":"2002","journal-title":"Proc Amer Soc Clin Oncol"},{"key":"2021122209333294200_R19","first-page":"627a","article-title":"Results of a multivariate analysis of prognostic factors of overall survival of patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib (ZD1839) in combination with platinum-based chemotherapy (CT) in two large phase III trials (INTACT 1 and 2)","volume":"22","author":"Giaccone","year":"2003","journal-title":"Proc Amer Soc Clin Oncol"},{"key":"2021122209333294200_R20","article-title":"ZD1839 (Iressa) in advanced bronchioloalveolar carcinoma (BAC): a preliminary report of SWOG S0126 [abstract]","volume-title":"Tenth World Conference on Lung Cancer","author":"West","year":"2003"},{"key":"2021122209333294200_R21","first-page":"619a","article-title":"The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) shows promising activity in patients with bronchioloalveolar cell carcinoma (BAC): preliminary results of a phase II trial","volume":"22","author":"Miller","year":"2003","journal-title":"Proc Amer Soc Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.9-2-232","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.9-2-232","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/9\/2\/232\/41844504\/oncolo_9_2_232.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/9\/2\/232\/41844504\/oncolo_9_2_232.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T16:55:07Z","timestamp":1640192107000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/9\/2\/232\/6387903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4,1]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2004,4,1]]},"published-print":{"date-parts":[[2004,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.9-2-232","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2004,4,1]]},"published":{"date-parts":[[2004,4,1]]}}}